Physician profile
Sushma Sadasivan
NPI 1609843739
$4,437.50
in general payments reported to CMS, 2019-2025
33 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $875 · 2021: $62.80 · 2022: $250 · 2023: $485 · 2024: $716 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,245.79 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $670.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $664.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $395.92 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $360.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.35 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $267.16 | 2019-2022 | |
| Lilly USA, LLC | $251.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $243.18 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $229.89 | 2019-2020 | |
| Abbott Laboratories | $150.20 | 2022-2025 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $132.47 | 2023 | Contrave, Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $97.01 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $80.76 | 2019-2020 | |
| Dynavax Technologies Corporation | $66.14 | 2019-2024 | Heplisav-B |
| Sanofi Pasteur INC. | $62.62 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.97 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cranial Technologies, INC | $48.03 | 2019-2025 | Doc Band |
| Amarin Pharma, INC. | $44.98 | 2020 | |
| Corcept Therapeutics | $44.63 | 2025 | Korlym |
| Abbvie INC. | $31.77 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.25 | 2022 | |
| Hologic Sales and Service, LLC | $24.62 | 2025 | Thinprep 2000 Processor, Aptima |
| Olympus America INC. | $23.74 | 2025 | Itind System |
| Vertex Pharmaceuticals Incorporated | $23.44 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $23.05 | 2025 | Lumryz |
| Astellas Pharma US INC | $22.35 | 2023 | Veozah |
| Actelion Pharmaceuticals US, INC. | $20.93 | 2024 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $20.81 | 2023 | Wakix |
| Shire North American Group INC | $19.01 | 2019 | |
| Inari Medical, INC. | $16.02 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Circassia INC. | $15.79 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.47 | 2024 | Crysvita |
| Rgh Enterprises LLC | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushma Sadasivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.